Risk assessment for recurrent venous thrombosis

@article{Kyrle2010RiskAF,
  title={Risk assessment for recurrent venous thrombosis},
  author={Paul A. Kyrle and Frits Richard Rosendaal and Sabine Eichinger},
  journal={The Lancet},
  year={2010},
  volume={376},
  pages={2032-2039}
}
Venous thrombosis is a common disease that frequently recurs. Recurrence can be prevented by anticoagulants, albeit at the cost of bleeding. Thus, assessment of the risk of recurrence is important to balance the risks and benefits of anticoagulation treatment. Many clinical and laboratory risk factors for recurrent venous thrombosis have been established. Nevertheless, prediction of recurrence in an individual patient remains a challenge. Detection of some laboratory markers is associated with… Expand
Clinical scores to predict recurrence risk of venous thromboembolism.
TLDR
Several such scoring models which can be used to assess the risk of recurrent VTE have been developed and await prospective validation before they can be applied in daily routine care. Expand
Venous thrombosis: who should be screened for thrombophilia in 2014?
  • P. Kyrle
  • Medicine
  • Polskie Archiwum Medycyny Wewnetrznej
  • 2014
TLDR
Routine laboratory thrombophilia screening is no longer warranted for VTE patients with a distinct laboratory abnormality, because the evidence that they increase the recurrence risk is weak and the practice has failed. Expand
Scoring Systems for Estimating the Risk of Recurrent Venous Thromboembolism.
TLDR
This article highlights the advantages and disadvantages of clinical prediction rules to estimate the absolute risk of VTE recurrence in individual patients, presenting three different prediction rules that have been published so far. Expand
Predicting the risk of venous thromboembolism recurrence
  • J. Heit
  • Medicine
  • American journal of hematology
  • 2012
TLDR
A recommendation for secondary prophylaxis should be individualized based on the risk for recurrent VTE (especially fatal pulmonary embolism) and bleeding, and the appropriateness of secondaryProphylactic should be continuously reevaluated and stopped if the benefit no longer exceeds the risk. Expand
Predicting recurrent venous thromboembolism in cancer: is it possible?
TLDR
A risk assessment model (RAM) for predicting recurrent VTE has been presented and the Ottawa score allows stratification of cancer patients according to their VTE recurrence risk, which was successfully validated in more than 800 patients from 2 prospective VTE treatment studies. Expand
Anticoagulation after venous thromboembolism. Deciding on the optimal duration.
TLDR
Novel approaches to optimize the management of patients with unprovoked VTE are the use of prediction models which link clinical patient characteristics with laboratory testing to discriminate between patients with a low risk (who may discontinue anticoagulation) and those with high risk (in whom long term antICOagulation is justified). Expand
Laboratory thrombophilia screening: essentials for hematologists
  • P. Kyrle
  • memo - Magazine of European Medical Oncology
  • 2021
Venous thromboembolism (VTE) is a chronic disease which tends to recur, in particular in patients with a first unprovoked VTE. Recurrence can be prevented by anticoagulants but at the price ofExpand
Overview and assessment of risk factors for pulmonary embolism.
TLDR
There are a plethora of risk factors for venous thromboembolism and pulmonary emboli and these factors are grouped under the broad triad of hypercoagulability, stasis and injury to provide a framework for understanding. Expand
Long-term management of venous thromboembolism: a 61-year-old woman with unprovoked venous thromboembolism.
TLDR
The case of Ms W, a woman with unprovoked venous thromboembolism and hemorrhagic event while receiving anticoagulation, is used to illustrate clinical decision making to determine ongoing treatment. Expand
Prognosis and Monitoring of VTE
TLDR
It is imperative that clinicians monitor patients for complications from VTE and the chosen therapy, as patients with deep vein thrombosis carry a higher risk of VTE recurrence and cardiac comorbidities. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 105 REFERENCES
Residual Venous Thrombosis as a Predictive Factor of Recurrent Venous Thromboembolism
TLDR
Recurrent thromboembolism was more frequent among those showing persistent residual thrombosis rather than early vein recanalization and might help clinicians adjust the duration of oral anticoagulant therapy on an individual basis in patients who have had an episode of DVT. Expand
Identification of Patients at Low Risk for Recurrent Venous Thromboembolism by Measuring Thrombin Generation
TLDR
Measurement of thrombin generation identifies patients at low risk for recurrent VTE, and investigates the relationship between recurrence of VTE and a simple global coagulation assay measuring throm bin generation. Expand
The risk of recurrent venous thromboembolism in patients with and without factor V Leiden.
TLDR
Balancing the risk of recurrent VTE and bleeding from oral anticoagulants, patients with factor V Leiden are not likely to benefit from oral anti-coagulant therapy extended beyond six months. Expand
Risk Assessment of Recurrence in Patients With Unprovoked Deep Vein Thrombosis or Pulmonary Embolism: The Vienna Prediction Model
TLDR
By use of a simple scoring system, the assessment of the recurrence risk in patients with a first unprovoked VTE and without strong thrombophilic defects can be improved. Expand
Duration of Anticoagulant Therapy After Venous Thromboembolism
TLDR
Among patients with unprovoked proximal deep vein thrombosis or pulmonary emblism, more than one previous episode of VTE, presentation as pulmonary embolism, male sex, and a positive D-dilmer test 1 month after stopping anticoagulant therapy, particularly favor indefinite antICOagulants. Expand
Family history for venous thromboembolism and the risk for recurrence.
TLDR
A family history for venous thromboembolism does not segregate patients into high- or low-risk categories and is not suitable to identify patients at increased risk for recurrent venous Thrombosis. Expand
The risk of recurrent venous thromboembolism in men and women.
TLDR
The risk of recurrent venous thromboembolism is higher among men than women and remains unchanged after adjustment for age, the duration of anticoagulation, and the presence or absence of a first symptomatic pulmonary embolism. Expand
D-dimer levels and risk of recurrent venous thromboembolism.
TLDR
Patients with a first spontaneous VTE and a D-dimer level of less than 250 ng/mL after withdrawal of oral anticoagulation have a low risk of VTE recurrence, and a laboratory method that measures multifactorial thrombophilia is required. Expand
The risk of recurrent venous thromboembolism among patients with high factor IX levels
TLDR
High levels of FIX confer an increased risk of recurrent venous thromboembolism and enhance the risk of recurrence among patients with high FVIII. Expand
Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer.
TLDR
ETP and D-dimer are independent predictors of recurrent venous thromboembolism and assessing risk of recurrence can be optimized by combining these indicators of thrombin generation. Expand
...
1
2
3
4
5
...